S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
NASDAQ:VCEL

Vericel - VCEL Stock Forecast, Price & News

$23.20
-0.55 (-2.32%)
(As of 09/30/2022 09:02 PM ET)
Add
Compare
Today's Range
$23.12
$24.63
50-Day Range
$22.62
$32.54
52-Week Range
$22.06
$52.87
Volume
530,800 shs
Average Volume
487,241 shs
Market Capitalization
$1.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.33

Vericel MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.9% Upside
$37.33 Price Target
Short Interest
Bearish
16.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Vericel in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.23) to $0.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

1015th out of 1,095 stocks

Biological Products, Except Diagnostic Industry

165th out of 171 stocks

VCEL stock logo

About Vericel (NASDAQ:VCEL) Stock

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Stock News Headlines

Vericel (VCEL) Q2 2022 Earnings Call Transcript
Vericel Reports Second Quarter 2022 Financial Results
Vericel Q2 2022 Earnings Preview - Seeking Alpha
See More Headlines
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Company Calendar

Last Earnings
11/08/2021
Today
10/02/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCEL
Employees
281
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$37.33
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+60.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-7,470,000.00
Pretax Margin
-10.81%

Debt

Sales & Book Value

Annual Sales
$156.18 million
Book Value
$3.64 per share

Miscellaneous

Free Float
44,725,000
Market Cap
$1.09 billion
Optionable
Optionable
Beta
2.06

Social Links


Key Executives

  • Mr. Dominick C. Colangelo Esq. (Age 58)
    CEO, Pres & Director
    Comp: $1.36M
  • Mr. Joseph Anthony Mara Jr. (Age 46)
    CFO & Treasurer
    Comp: $636.24k
  • Mr. Michael  HalpinMr. Michael Halpin (Age 61)
    Chief Operating Officer
    Comp: $672.86k
  • Mr. Sean C. FlynnMr. Sean C. Flynn (Age 48)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $556.66k
  • Dr. Jonathan M. Hopper FRCSEd. (Age 60)
    M.B. Ch.B., Chief Medical Officer
    Comp: $578.36k
  • Mr. Jonathan Siegal
    Principal Accounting Officer, VP & Corp. Controller
  • Mr. Eric Burns
    Exec. Director of Financial Planning and Analysis & Investor Relations
  • Mr. Patrick J. Fowler
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Heidi Hassen
    VP of HR
  • Mr. Roland DeAngelis
    Sr. VP of Commercial Operations













VCEL Stock - Frequently Asked Questions

Should I buy or sell Vericel stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings
or view top-rated stocks.

What is Vericel's stock price forecast for 2022?

3 brokerages have issued 1 year price targets for Vericel's shares. Their VCEL share price forecasts range from $33.00 to $45.00. On average, they anticipate the company's share price to reach $37.33 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price.
View analysts price targets for VCEL
or view top-rated stocks among Wall Street analysts.

How have VCEL shares performed in 2022?

Vericel's stock was trading at $39.30 at the start of the year. Since then, VCEL shares have decreased by 41.0% and is now trading at $23.20.
View the best growth stocks for 2022 here
.

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VCEL earnings forecast
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.08. The biotechnology company had revenue of $34.51 million for the quarter, compared to analyst estimates of $38.07 million. Vericel had a negative trailing twelve-month return on equity of 9.75% and a negative net margin of 10.60%. Vericel's revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.08 EPS.

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $178.00 million-$189.00 million, compared to the consensus revenue estimate of $182.20 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $23.20.

How much money does Vericel make?

Vericel (NASDAQ:VCEL) has a market capitalization of $1.09 billion and generates $156.18 million in revenue each year. The biotechnology company earns $-7,470,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Vericel have?

The company employs 281 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (800) 556-0311, via email at ir@vcel.com, or via fax at 617-588-5554.

This page (NASDAQ:VCEL) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.